Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

90.51 +0.64 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 550,617
Open 90.21
Bid (Size) 87.07 (1)
Ask (Size) 90.74 (1)
Prev. Close 89.87
Today's Range 88.02 - 90.65
52wk Range 55.02 - 98.40
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Under-the-Radar Biotech Stock to Buy and Hold
It could be an industry giant in the making. 
Via The Motley Fool
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders 
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+17.45%
+17.45%
1 Month
+0.96%
+0.96%
3 Month
+14.67%
+14.67%
6 Month
+21.39%
+21.39%
1 Year
+35.39%
+35.39%

More News

Read More
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Unveiling 14 Analyst Insights On Axsome Therapeutics
Via Benzinga
A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 9 Analysts
Via Benzinga
Axsome Therapeutics to Participate in Investor Conferences in September
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
New Study Reveals How Classical Music Could Revolutionize Depression Care
Via PressReach
Exposures Product Safety
Decoding 9 Analyst Evaluations For Axsome Therapeutics
Via Benzinga
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Axsome Therapeutics Stock Is Sinking Today
Via The Motley Fool
Axsome Plunges On Wide Losses, But Its Biggest Moneymaker Tacks On 135% Growth
Via Investor's Business Daily
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
Via FinancialNewsMedia
Exposures Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
Via Benzinga
7 Biotech Stocks to Keep on Your Clinical Radar
Via InvestorPlace
Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Via Benzinga
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Via The Motley Fool
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The 3 Best Biotech Stocks to Buy in July 2024
Via InvestorPlace
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.